8.32

6.20% -0.55

Bicycle Therapeutics Plc Adr (BCYC)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$8.87

Offen:

$8.97

24-Stunden-Volumen:

298.16K

Relative Volume:

1.09

Marktkapitalisierung:

$414.91M

Einnahmen:

$36.90M

Nettoeinkommen (Verlust:

$-166.28M

KGV:

-2.5289

EPS:

-3.29

Netto-Cashflow:

$-203.53M

1W Leistung:

-0.60%

1M Leistung:

+18.86%

6M Leistung:

+27.41%

1J Leistung:

-66.77%

1-Tages-Spanne:

$8.30

$9.0998

1-Wochen-Bereich:

$7.80

$9.1592

52-Wochen-Spanne:

$6.10

$28.67

Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile

Firmenname

Bicycle Therapeutics Plc Adr

Sektor

Healthcare (1140)

Branche

Biotechnology (637)

Telefon

011441223261503

Adresse

BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE

Mitarbeiter

305

Twitter

@Bicycle_tx

Nächster Verdiensttermin

2025-08-08

Neueste SEC-Einreichungen

BCYC's Discussions on Twitter

Vergleichen Sie BCYC mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BCYC Bicycle Therapeutics Plc Adr	8.32	614.75M	36.90M	-166.28M	-203.53M	-3.29
VRTX Vertex Pharmaceuticals Inc	407.79	106.37B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	460.46	59.90B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	564.63	60.40B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	796.92	49.56B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.10	36.88B	4.56B	-176.77M	225.30M	-1.7177

Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-11-08	Eingeleitet	Stephens	Equal-Weight
2024-09-06	Eingeleitet	RBC Capital Mkts	Outperform
2024-08-07	Herabstufung	B. Riley Securities	Buy → Neutral
2023-09-11	Hochstufung	B. Riley Securities	Neutral → Buy
2022-08-31	Eingeleitet	Cowen	Outperform
2022-07-28	Eingeleitet	Barclays	Overweight
2022-07-06	Fortgesetzt	Canaccord Genuity	Buy
2022-04-13	Herabstufung	B. Riley Securities	Buy → Neutral
2022-04-07	Fortgesetzt	Cantor Fitzgerald	Overweight
2022-02-14	Eingeleitet	Morgan Stanley	Equal-Weight
2021-12-17	Eingeleitet	SVB Leerink	Outperform
2021-12-09	Eingeleitet	Needham	Buy
2021-09-30	Eingeleitet	B. Riley Securities	Buy
2021-04-20	Eingeleitet	JMP Securities	Mkt Outperform
2020-10-12	Eingeleitet	Cantor Fitzgerald	Overweight
2020-06-12	Eingeleitet	Oppenheimer	Outperform
2020-04-17	Eingeleitet	H.C. Wainwright	Buy
2019-11-14	Eingeleitet	ROTH Capital	Buy
2019-09-11	Hochstufung	Goldman	Neutral → Buy
2019-06-17	Eingeleitet	Canaccord Genuity	Buy
2019-06-17	Eingeleitet	Goldman	Neutral
2019-06-17	Eingeleitet	Jefferies	Buy
2019-06-17	Eingeleitet	Piper Jaffray	Overweight

Alle ansehen

Bicycle Therapeutics Plc Adr Aktie (BCYC) Neueste Nachrichten

Oct 12, 2025

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Oct 12, 2025

Oct 10, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Trading Up 10.5%What's Next? - MarketBeat

Oct 10, 2025

Oct 06, 2025

Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 3,231 Shares - MarketBeat

Oct 06, 2025

Insider Selling: Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells 2,263 Shares of Stock - MarketBeat

Oct 06, 2025

Oct 03, 2025

Bicycle Therapeutics Sees Unusually Large Options Volume (NASDAQ:BCYC) - Defense World

Oct 03, 2025

Oct 02, 2025

Stock Traders Purchase High Volume of Bicycle Therapeutics Call Options (NASDAQ:BCYC) - MarketBeat

Oct 02, 2025

Sep 29, 2025

Goldman Sachs Group Inc. Takes Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World

Sep 29, 2025

Sep 24, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Trading Up 7.8%Here's Why - MarketBeat

Sep 24, 2025

Sep 22, 2025

126,062 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Acquired by Acadian Asset Management LLC - MarketBeat

Sep 22, 2025

Sep 20, 2025

Analysts Set Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Price Target at $22.22 - MarketBeat

Sep 20, 2025

Sep 18, 2025

126,062 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Bought by Acadian Asset Management LLC - Defense World

Sep 18, 2025

Sep 17, 2025

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Sep 17, 2025

Sep 11, 2025

Cubist Systematic Strategies LLC Sells 2,650 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World

Sep 11, 2025

Sep 09, 2025

Bicycle Therapeutics appoints oncology veterans Dansey and Hoppenot to board - Investing.com India

Sep 09, 2025

Sep 06, 2025

Caption Management LLC Sells 81,517 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Sep 06, 2025

Sep 05, 2025

Armistice Capital LLC Has $22.69 Million Holdings in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Sep 05, 2025

Sep 04, 2025

Long Focus Capital Management LLC Acquires 750,661 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Sep 04, 2025

Sep 03, 2025

Bicycle Therapeutics PLC Sponsored ADR $BCYC Stock Holdings Cut by Tybourne Capital Management HK Ltd. - MarketBeat

Sep 03, 2025

Aug 29, 2025

Bicycle Toxin Conjugates Clinical Trials FDA Approval Proprietary Technology Cancer Drugs Report 2025 - GlobeNewswire Inc.

Aug 29, 2025

Aug 27, 2025

Candriam S.C.A. Acquires 117,331 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat

Aug 27, 2025

Aug 20, 2025

Analysts’ Weekly Ratings Updates for Bicycle Therapeutics (BCYC) - Defense World

Aug 20, 2025

Aug 13, 2025

Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com

Aug 13, 2025

Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress By Investing.com - Investing.com South Africa

Aug 13, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Given New $13.00 Price Target at Morgan Stanley - Defense World

Aug 13, 2025

Aug 08, 2025

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results - Placera.se

Aug 08, 2025

Aug 01, 2025

Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? - MSN

Aug 01, 2025

Jul 31, 2025

Rice Biotech Launch Pad adds TPG Life Sciences’ Carolyn Ng to board - Investing.com

Jul 31, 2025

Jul 29, 2025

Coursera (NYSE:COUR) Sees Strong Trading Volume on Analyst Upgrade - Defense World

Jul 29, 2025

Jul 17, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Teacher Retirement System of Texas - Defense World

Jul 17, 2025

Principal Financial Group Inc. Boosts Stock Position in Schneider National, Inc. (NYSE:SNDR) - Defense World

Jul 17, 2025

Principal Financial Group Inc. Purchases 1,695 Shares of Monarch Casino & Resort, Inc. (NASDAQ:MCRI) - Defense World

Jul 17, 2025

Teacher Retirement System of Texas Has $465,000 Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World

Jul 17, 2025

Teacher Retirement System of Texas Sells 1,266 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World

Jul 17, 2025

Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 17, 2025

William Blair Brokers Decrease Earnings Estimates for TLX - Defense World

Jul 17, 2025

Principal Financial Group Inc. Purchases 5,315 Shares of Aaron’s Holdings Company, Inc. (NYSE:PRG) - Defense World

Jul 17, 2025

First Northwest Bancorp (FNWB) Expected to Announce Quarterly Earnings on Thursday - Defense World

Jul 17, 2025

Principal Financial Group Inc. Raises Stake in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) - Defense World

Jul 17, 2025

Jul 04, 2025

The Bank of Nova Scotia (TSE:BNS) Receives Average Rating of “Hold” from Analysts - Defense World

Jul 04, 2025

Jun 22, 2025

Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up – Should You Buy? - Defense World

Jun 22, 2025

May 07, 2025

Market Update: Bicycle Therapeutics Plc ADR (BCYC) Sees Negative Movement, Closing at 7.40 - DWinneX

May 07, 2025

May 01, 2025

Bicycle Therapeutics earnings missed by $0.03, revenue topped estimates - Investing.com South Africa

May 01, 2025

Apr 24, 2025